Is Ultragenyx Pharmaceutical, Inc. overvalued or undervalued?

As of 20 February 2018, the valuation grade for Ultragenyx Pharmaceutical, Inc. has moved from does not qualify to risky, indicating a heightened level of concern regarding its financial health. The company is currently overvalued, as evidenced by its significant negative ratios, including a Price to Book Value of 24.36 and an EV to EBITDA of -8.10, which reflect its loss-making status. Additionally, the Return on Capital Employed (ROCE) stands at a staggering -102.05%, and the Return on Equity (ROE) is an alarming -377.52%.
In comparison to its peers, Ultragenyx's valuation metrics are notably unfavorable. For instance, Corcept Therapeutics, Inc. is classified as expensive with a P/E ratio of 60.68, while Madrigal Pharmaceuticals, Inc. is also risky with a P/E of -15.85. This stark contrast highlights Ultragenyx's struggles within the industry. Furthermore, the company's stock has underperformed against the S&P 500, with a year-to-date return of -12.46% compared to the index's 2.44%, reinforcing the notion that Ultragenyx is currently overvalued.